Every theatrically released Star Wars movie since Disney's acquisition of Lucasfilm has introduced at least one new type of ...

Star Wars' video games span various genres. The Battlefront series is a Battlefield-style shooter, with two armies battling each other to take control of objectives across different maps like Hoth, ...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on breakthrough therapies, today announced that it has regained full compliance with Nasdaq's minimum bid ...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies, today announced that they will host a virtual Key Opinion Leader (KOL) event on ...

NEW YORK - Hoth Therapeutics, Inc. (NASDAQ:HOTH), a microcap biotech company with a market capitalization of $16.25 million, reported that its investigational drug HT-001 met at least one primary ...

Hoth Therapeutics will host a Key Opinion Leader (KOL) event on June 24, 2025, at 3:30PM EST to highlight recent clinical progress with HT-001, a novel topical therapeutic developed to address ...

NEW YORK - Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biotech firm with strong financial health showing more cash than debt on its balance sheet, and Silo Pharma, Inc. (NASDAQ:SILO) announced Wednesday ...

(RTTNews) - Hoth Therapeutics (HOTH), Tuesday reported that its experimental topical gel, HT-001, achieved primary efficacy in at least one key dermatologic metric for 100 percent of patients in ...

NEW YORK, June 18, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on breakthrough therapies, today announced that it has regained ...

(RTTNews) - Hoth Therapeutics (HOTH) and Silo Pharma (SILO) announced the formation of a joint venture to develop and commercialize a treatment for obesity and metabolic disease based on ...

If you’ve tried launching Star Wars: Battlefront 2 recently and ran into error code 770, you’re not alone.

Hoth Therapeutics' HT-001 Achieves 100% Response Rate in at least one endpoint in Phase 2a Trial in PK Patients for EGFR Inhibitor-Related Skin Toxicities. Hoth Therapeutics will host a Key ...